Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Second Time Around: Cephalon Buys Ception Based On Cinquil Data In Asthma

This article was originally published in The Pink Sheet Daily

Executive Summary

Cephalon passed on a first option to buy Ception Therapeutics, but will now acquire the company for $250 million following encouraging Phase II results.

You may also be interested in...



On The Respiratory Horizon: A Wave Of Biologics For Asthma

Several antibody drugs are in late-stage development to treat severe asthma and could reach the market in the next two years. But competition for niche subsets of patients will be fierce, and tailoring the right medications to the right patients to justify the higher cost of treatment will require advances in biomarker development.

As Cephalon Rejects Valeant Bid, Valeant Officially Goes Hostile

Valeant's offer undervalues Cephalon, its assets and its prospects, and "ignores the proven ability" of its management to maximize opportunities, Cephalon's board says.

As Cephalon Rejects Valeant Bid, Valeant Officially Goes Hostile

Valeant's offer undervalues Cephalon, its assets and its prospects, and "ignores the proven ability" of its management to maximize opportunities, Cephalon's board says.

Related Content

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel